Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,119 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05190068

Conditions
B-cell Non-Hodgkin's Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Beijing Chao-Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Xiamen University Xiameng, Fujian, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Guangxi Medical University cancer Hospital & Guangxi Cancer Institute Nanning, Guangxi, China
View all 22 locations
View Trial Details
Completed

A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

NCT04317066

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Nagoya University Hospital ( Site 0002) Nagoya, Aichi-ken, Japan
  • Hokkaido University Hospital ( Site 0006) Sapporo, Hokkaido, Japan
  • Kindai University Hospital ( Site 0001) Sayama, Osaka, Japan
  • National Hospital Organization Disaster Medical Center ( Site 0007) Tachikawa, Tokyo, Japan
View Trial Details
Completed

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

NCT04849351

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • The Second Hospital of Anhui Medical University Hefei, Anhui, China
  • Beijing Chao-yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
View all 58 locations
View Trial Details
Completed

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

NCT04105010

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • Winship Cancer Institute Atlanta, Georgia, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 50 locations
View Trial Details
Completed

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

NCT00588991

Conditions
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, +55 more
Locations
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details

Related conditions